reported that ACE2, as a receptor of SARS-CoV-2, had low expression (2.6%) in hepatocytes but the high expression in cholangiocytes, suggesting that COVID-19 may damage bile duct cells, and speculate that liver injury in patients with COVID-19 may be caused by cholangiocyte dysfunction (Chai et al., 2020). The gene discussed is ACE2; the disease is COVID-19.